Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-02-24 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
2021年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a 2021 annual performance preliminary announcement (年度业绩快报公告) and contains key financial data and performance indicators for the year 2021. It explicitly states that the data are preliminary and unaudited, and the final audited data will be disclosed in the formal 2021 annual report. The document is relatively short (1648 characters) and serves as an initial earnings summary rather than a full annual report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not the full detailed report. Therefore, the document should be classified as an Earnings Release (ER). FY 2021
2022-02-24 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an external investment by the company into a private equity fund that will invest in another company. It details the investment amount, the nature of the investment, the involved parties, and the strategic rationale and risks. There are no financial statements or detailed financial performance data included. The document is relatively short (3207 characters) and serves as a formal disclosure of the investment transaction rather than a comprehensive financial report. This fits the category of a Capital/Financing Update (CAP), as it updates on the company's financing activities and capital allocation.
2022-02-23 Chinese
2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the "2022 First Extraordinary General Meeting" of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the meeting date, location, attendance, agenda items, voting results, and legal opinions on the meeting's validity. The content focuses on the official announcement of shareholder meeting resolutions and voting outcomes rather than the meeting materials or detailed reports. The document length is short (1486 characters), and it is clearly an announcement of voting results from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-02-09 Chinese
2022年第一次临时股东大会通知公告
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2022 first extraordinary general meeting of shareholders (临时股东大会) for Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the meeting date, voting methods, attendees, agenda items, and registration procedures. It does not contain any financial statements, audit results, or detailed financial data. The document is primarily an announcement about the meeting itself, not the results or materials of the meeting. It is also relatively short (2155 characters). Therefore, it fits the category of a regulatory announcement related to shareholder meetings but not the meeting materials or voting results. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-01-23 Chinese
独立董事关于第四届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the independent directors of Yunnan Biovalley Pharmaceutical Co., Ltd. regarding their independent opinion on a board meeting resolution about using idle funds to purchase financial products. It references the board meeting date and legal compliance but does not contain financial statements or detailed financial data. The document is short (740 characters) and serves as an official opinion and announcement related to board decisions rather than a full management report or financial report. It is not a full Annual Report, Interim Report, or Earnings Release. It is also not a regulatory certification or a voting result announcement. The content fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on company decisions.
2022-01-23 Chinese
第四届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting, including details about meeting attendance, agenda items, and voting results. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. It specifically relates to board decisions and meeting outcomes, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. Therefore, the classification is MANG with high confidence.
2022-01-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.